This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma (TheraSphere)

This study is currently recruiting participants.
See Contacts and Locations
Verified November 2016 by Nadine Abi-Jaoudeh, University of California, Irvine
BTG International Inc.
Information provided by (Responsible Party):
Nadine Abi-Jaoudeh, University of California, Irvine Identifier:
First received: December 27, 2007
Last updated: December 29, 2016
Last verified: November 2016

The purpose of this protocol is to provide TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. The effect on the tumor and any side effects of TheraSphere treatment will be examined. This study will provide supervised and limited access to TheraSphere treatment at University California Irvine Medical Center.

TheraSphere is a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. When Y-90 is incorporated into very tiny glass beads (TheraSphere), it can be injected to the liver through blood vessels supplying the liver. This allows a large dose of radiation to be delivered to the tumor with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue. The radiation from TheraSphere is contained within the body and becomes minimally active within 7 days after treatment due to physical decay. The glass beads remain in the body, but do not cause any health problems. TheraSphere has been approved for use in the treatment of liver cancer in the United States by the Food and Drug Administration on a limited basis.

Condition Intervention
Hepatocellular Carcinoma Liver Cancer Liver Neoplasm Primary Liver Cancer Device: TheraSphere

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Humanitarian Device Exemption Treatment Protocol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma

Resource links provided by NLM:

Further study details as provided by Nadine Abi-Jaoudeh, University of California, Irvine:

Primary Outcome Measures:
  • The protocol allows for prospective collection of data. There is no randomization to an alternative form of therapy. However, we measure tumor response after treatment based on CT scans and tumor markers. [ Time Frame: Every 3-6 months ]

Secondary Outcome Measures:
  • Evaluate for side effects [ Time Frame: Every 1-2 months ]

Estimated Enrollment: 130
Study Start Date: May 2002
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
TheraSphere® treatment
TheraSphere® treatment will be performed in the outpatient setting. The effect on the tumor and any side effects of TheraSphere® HUD treatment will be examined. This is not a research study and there are no comparison or experimental treatments being used. Within 14 days of initial treatment, reverification of eligibility will be confirmed. If review of eligibility indicates an uncorrectable risk of flow to the gastrointestinal organs or risk of shunting to the lungs, treatment will not be administered. In this event, the patient will receive alternative treatment (chemoembolization) or no treatment. If the patient remains eligible, TheraSphere® will be administered within 14 days. All patients will be evaluated at 30 days post-treatment to assess clinical experience and adverse effects. Subsequently, patient status will be followed via communication with the referring oncologist to determine disease status and survival. Survival surveillance will continue up to 24 months.
Device: TheraSphere
Given IV

Detailed Description:

This protocol provides TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. Patients with hepatocellular carcinoma will be evaluated for eligibility for this treatment with the following: physical examination, medical history, blood tests requiring approximately 2 tablespoons of blood, EKG, CT or MR of chest to examine lungs, CT or magnetic resonance (MR) of abdomen to evaluate liver, stomach and intestines, and bone scan to rule out spread of disease to bones. If eligible on initial screening, patients will proceed to a second stage of screening, including an hepatic angiogram to confirm treatment can be provided safely and to highlight the blood vessels supplying the liver, and a nuclear medicine study (Tc-99m MAA scan) to display the blood flow to the lungs, stomach and intestines.

When it is determined treatment can be delivered safely, patients will receive TheraSphere via the hepatic artery through blood vessels supplying the liver on an outpatient basis.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of intrahepatic carcinoma. The histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as Alpha-fetoprotein assay (AFP) (clinical diagnosis).
  • The cancer must be unresectable.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0 - 2
  • Age ≥ 18 years.
  • Able to comprehend and read the study information sheet in accordance with institutional and federal guidelines.

Exclusion Criteria:

  • Any pre-treatment laboratory findings within 15 days of treatment demonstrating:

    • Absolute granulocyte count ≤ 1,500/ul
    • Platelet count ≤ 75,000/μl
    • Serum creatinine ≥ 2.0 mg/dl
    • Serum bilirubin ≥ 2.0 mg/dl
  • Any of the following contraindications to angiography and selective visceral catheterization:

    • History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine
    • Bleeding diathesis, not correctable by usual forms of therapy
    • Severe peripheral vascular disease that would preclude catheterization.
  • Portal hypertension with portal venous shunt away from the liver.
  • Evidence of potential delivery of greater than 16.5 millicurie (mCi) (30 Gy absorbed dose) of radiation to the lungs on either: 1) first TheraSphere administration; or 2) cumulative delivery of radiation to the lungs > 30 Gy over multiple treatments.
  • Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow.
  • Significant extrahepatic disease representing an imminent life-threatening outcome.
  • Severe liver dysfunction or pulmonary insufficiency.
  • Active uncontrolled infection.
  • Significant underlying medical or psychiatric illness.
  • Pregnant women may not participate.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00906984

Contact: Chao Family Comprehensive Cancer Center University of California, Irvine Medical Center (877) 827-8839

United States, California
Chao Family Comprehensive Cancer Center Recruiting
Orange, California, United States, 92868
Principal Investigator: David K Imagawa, MD, PhD         
Sponsors and Collaborators
Nadine Abi-Jaoudeh
BTG International Inc.
Principal Investigator: David K Imagawa, MD, PhD University of California, Irvine
  More Information

Additional Information:
Responsible Party: Nadine Abi-Jaoudeh, Dr. Nadine Abi-Jaoudeh, University of California, Irvine Identifier: NCT00906984     History of Changes
Other Study ID Numbers: UCI 01-61
CA60396 ( Other Grant/Funding Number: National Cancer Institute )
2002-2242 ( Other Identifier: University of California, Irvine )
Study First Received: December 27, 2007
Last Updated: December 29, 2016

Keywords provided by Nadine Abi-Jaoudeh, University of California, Irvine:
Hepatocellular carcinoma
Liver cancer
Primary liver cancer
Unresectable liver cancer
Unresectable hepatocellular carcinoma

Additional relevant MeSH terms:
Liver Neoplasms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases processed this record on September 21, 2017